StockData
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. (TARS) stock

TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 11/303% below fair value
$73.01−4.66 (-6.00%)

Close on Nov 20, 2026Market cap $3.20BP/E –Yield 0.00%

Tarsus Pharmaceuticals gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$161.80M–
Q1 FY2026Mar 31, 2026$152.66M+6006.3%
Q2 FY2025Jun 30, 2025$96.42M–
Q1 FY2025Mar 31, 2025$73.12M+395.6%
Q2 FY2023Jun 30, 2023$0-100.0%
Q1 FY2023Mar 31, 2023$2.50M+112.8%
Q3 FY2022Sep 30, 2022$0–
Q2 FY2022Jun 30, 2022$14.76M–
Q1 FY2022Mar 31, 2022$506.00K–
Q3 FY2021Sep 30, 2021$1.18M–

More Tarsus Pharmaceuticals figures

See a number that looks wrong?